Researchers can view published data on antibodies directly on the website to help better understand antibody performance
CARLSBAD, Calif., July 9, 2018 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, today announced it has signed an agreement with BenchSci to utilize its proprietary machine learning platform to mine antibody data published in peer-reviewed scientific journals. The data and associated application information will be displayed on product-specific webpages to help scientists make informed decisions about the optimal antibodies to use in their experiments.
Prior to the availability of the platform on Thermo Fisher’s site, researchers were forced to rely on scientific search engines, sift through numerous papers, then tab back and forth between the published studies and product websites. The process could take hours or even days but is now significantly reduced to minutes by extracting key information and figures from open- and closed-access papers.
An image gallery on Thermo Fisher’s relevant antibody product pages will incorporate data generated by BenchSci’s platform so visitors on the website can review both internal product development data and figures from peer-reviewed journals in one location. Additional published figures covering more antibodies will be added over time.
Poor antibody specificity or application performance can significantly hinder the ability to obtain good results, which can cause critical research delays. Choosing wrong or underperforming antibodies result in a lack of reproducibility, wasted time and wasted resources. Researchers need antibodies that bind to the right target and work in their applications every time.
“Data is absolutely critical to ensuring that scientists can make high confidence decisions about what antibody reagent is likely to be most appropriate for their application of interest,” said Dara Wright, vice president and general manager of protein and cell analysis, Thermo Fisher Scientific. “Far too much time and money is wasted on the use of antibodies which don’t meet expectations. This new capability, coupled with our internal validation initiatives, is a meaningful step forward.”
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.
Media Contact Information:
Mauricio Minotta, Thermo Fisher Scientific
+1 760 929 2456
mauricio.minotta@thermofisher.com
SOURCE Thermo Fisher Scientific